tiprankstipranks
KalVista Pharmaceuticals (KALV)
NASDAQ:KALV
US Market
KALV
KalVista Pharmaceuticals
RESEARCH TOOLSreports
Want to see KALV full AI Analyst Report?

KalVista Pharmaceuticals (KALV) Income Statement

618 Followers

KalVista Pharmaceuticals Income Statement

Last quarter (Q3 2026), KalVista Pharmaceuticals's total revenue was $59.92M, an increase of Infinity% from the same quarter last year. In Q3, KalVista Pharmaceuticals's net income was $-5.37M. See KalVista Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Apr 25Apr 24Apr 23Apr 22
Total Revenue
$ 73.62M$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ 67.54M$ 0.00$ -86.17M$ 0.00$ 0.00
Operating Expenses
$ 239.38M$ 188.00M$ 54.28M$ 110.87M$ 96.61M
Depreciation and Amortization
$ 1.45M$ 941.00K$ 816.00K$ 718.00K$ 564.00K
EBITDA
$ -170.38M$ -173.33M$ -134.28M$ -94.37M$ -80.75M
Operating Income
$ -171.84M$ -188.00M$ -140.44M$ -110.87M$ -96.61M
Other Income/Expenses
$ 420.00K$ 7.94M$ 5.35M$ 17.96M$ 14.27M
Pretax Income
$ -171.42M$ -180.05M$ -135.10M$ -92.91M$ -82.34M
Net Income
$ -164.29M$ -183.44M$ -126.64M$ -92.91M$ -82.34M
Per Share Metrics
Basic EPS
$ -3.23$ -3.69$ -3.44$ -3.33$ -3.36
Diluted EPS
$ -3.23$ -3.69$ -3.44$ -3.33$ -3.36
Weighted Average Shares Outstanding
 50.90M 49.65M 36.79M 27.89M 24.47M
Weighted Average Shares Outstanding (Diluted)
 50.90M 49.65M 36.79M 27.89M 24.47M
Currency in USD

KalVista Pharmaceuticals Earnings and Revenue History